ReviewJournal of hepatology2014
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.
Review in Journal of hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 203 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
203 citing papers in PubMed, 2 syntheses or guidelines pooled it, 314 citations in OpenAlex.
- Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis.Frontiers in medicine · 2026Pooled it
- Anticancer Potentials of the Lignan Magnolin: A Systematic Review.Molecules (Basel, Switzerland) · 2023Pooled it
- Trial
- Integrated expression profiling reveals molecular crosstalk between CFTR, FASN, FRAP (mTOR), and BANK1 in hepatocellular carcinoma.Scientific reports · 2026Article
- EMC3 as a Novel Biomarker and Driver of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Progression.Annals of surgical oncology · 2026Article
- Intermittent fasting enhances cancer therapyWorld journal of clinical oncology · 2026Review
- Article
- The many ways to inhibit translation by Sorafenib in liver cancer cells.Molecular and cellular biochemistry · 2026Article
- Royal Jelly-Derived Extracellular Vesicles: Key Bioactive Components Mediating Anti-Hepatocellular Carcinoma Activity.International journal of nanomedicine · 2026Article
- Unraveling Key Regulatory Pathways in Non-HCV-Induced Hepatocellular Carcinoma: Insights from Exclusively Mutated Genes and Prognostic Biomarkers.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Chemoprevention of hepatocellular carcinoma.Hepatology communications · 2025Review
- Hepatocellular Carcinoma Recurrence After Liver Transplantation: Current Insights and Future Directions.Journal of clinical medicine · 2025Review
- Long Non-Coding RNA IGFRIL Couples with PTBP1 to Destabilize IGFBP3 mRNA to Promote the IGF1R-AKT-mTOR Axis and Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- ATOX1 Promotes Hepatocellular Carcinoma Carcinogenesis via Activation of the c-Myb/PI3K/AKT Signaling Pathway.Journal of clinical and translational hepatology · 2025Article
- Exploring non-coding RNA expression profiles of AKR1B10P1, RP11-465B22.3, WASH8P, and NPM1P25 as a predictive model for hepatocellular carcinoma patient survival.Discover oncology · 2025Article
- αKG-induced oxidative stress and mTOR inhibition as a therapeutic strategy for liver cancer.Medical oncology (Northwood, London, England) · 2025Article
- Identification and characterization of cell niches in tissue from spatial omics data at single-cell resolution.Nature communications · 2025Article
- Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment.Cell death & disease · 2025Article
- The PI3K/Akt/mTOR Pathway: Immuno-Metabolic Orchestration in IR/MASH-Associated Hepatocellular Carcinoma.International journal of biological sciences · 2025Review
- TENT5A mediates the cancer-inhibiting effects of EGR1 by suppressing the protein stability of RPL35 in hepatocellular carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2024Article
143 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in response to nutrients, cellular energy stage and growth factors. mTOR is frequently up-regulated in cancer including hepatocellular carcinoma (HCC) and is associated with bad prognosis, poorly differentiated tumors, and earlier recurrence. Blocking mTOR with rapamycin and first generation mTOR inhibitors, called rapalogs, has shown promising reduction of HCC tumor growth in preclinical models. Currently, rapamycin/rapalogs are used in several clinical trials for the treatment of advanced HCC, and as adjuvant therapy in HCC patients after liver transplantation and TACE. A second generation of mTOR pathway inhibitors has been developed recently and is being tested in various clinical trials of solid cancers, and has been used in preclinical HCC models. The results of series of clinical trials using mTOR inhibitors in HCC treatment will emerge in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.